SCHEMBL734360

SCHEMBL734360

C=CCNc1nc(N)c2[nH]cnc2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.50
GDA Q9Y2T3 1/20 0.50
POLA1 P09884 2/20 0.47
CDK1 P06493 4/20 0.46
CDK2 P24941 3/20 0.46
CCNB1 P14635 2/20 0.46
CCNA2 P20248 2/20 0.46
CCNA1 P78396 2/20 0.46
MGMT P16455 1/20 0.46
KDR P35968 1/20 0.41
AURKB Q96GD4 1/20 0.41
MAPT P10636 1/20 0.40
PI4KA P42356 2/20 0.40
PI4K2B Q8TCG2 2/20 0.40
PI4K2A Q9BTU6 2/20 0.40
PI4KB Q9UBF8 2/20 0.40
HIF1A Q16665 1/20 0.40
LMNA P02545 1/20 0.40
DRD3 P35462 1/20 0.40
XDH P47989 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL669414 0.84 PDPK1 (0.49) PDPK1GDAPOLA1CDK1CDK2
SCHEMBL8588220 0.82 DPP4 (0.47) POLA1CDK1CDK2CCNB1CCNA2
SCHEMBL28274636 0.81 PDPK1 (0.56) PDPK1GDAPOLA1CDK1CDK2
SCHEMBL16145922 0.80 POLA1 (0.55) PDPK1GDAPOLA1CDK1CDK2
SCHEMBL8523000 0.78 INSR (0.39) CDK1CDK2CCNB1CCNA2CCNA1
SCHEMBL16146953 0.78 POLA1 (0.56) PDPK1GDAPOLA1CDK1CDK2
SCHEMBL8009122 0.78 CDK1 (0.57) PDPK1GDAPOLA1CDK1CDK2
SCHEMBL29138715 0.77 PDPK1 (0.50) PDPK1GDAPOLA1CDK1CDK2
SCHEMBL796828 0.77 CDK1 (0.59) PDPK1GDACDK1CDK2CCNB1
SCHEMBL16146295 0.77 PDPK1 (0.50) PDPK1GDAPOLA1CDK1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120156679-A1 METHODS FOR MAKING TRANSCRIPTION PRODUCTS EPICENTRE TECHNOLOGIES (US) 2012-06-21 US disclosed
US-8137911-B2 Using promoter sequences and RNA polymerase to generate nucleotide sequences corresponding to target gene sequences; gene expression inhibition and diagnostic probe generation CELLSCRIPT, INC. (US) 2012-03-20 US disclosed
US-7838270-B2 Target-dependent transcription using deletion mutants of N4 RNA polymerase THE UNIVERSITY OF CHICAGO (US) 2010-11-23 US disclosed
US-7659072-B2 Methods for using riboprimers for strand displacement replication of target sequences EPICENTRE TECHNOLOGIES CORPORATION (US) 2010-02-09 US disclosed
US-20080293107-A1 METHODS FOR USING RIBOPRIMERS FOR STRAND DISPLACEMENT REPLICATION OF TARGET SEQUENCES EPICENTRE TECHNOLOGIES CORPORATION (US) 2008-11-27 US disclosed
EP-1576188-B1 METHODS FOR USING RIBOPRIMERS FOR STRAND DISPLACEMENT REPLICATION OF TARGET SEQUENCES EPICT TECHNOLOGIES (US) 2008-10-15 EP disclosed
US-7413857-B2 Methods for using riboprimers for strand displacement replication of target sequences EPICENTRE TECHNOLOGIES (US) 2008-08-19 US disclosed
EP-1585824-A4 PREPARATION AND USE OF SINGLE-STRANDED TRANSCRIPTION SUBSTRATES FOR SYNTHESIS OF TRANSCRIPTION PRODUCTS CORRESPONDING TO TARGET SEQUENCES EPICT TECHNOLOGIES (US) 2008-01-02 EP disclosed
US-7101713-B1 DNA transformation efficiency by inhibiting host cell restriction EPICENTRE TECHNOLOGIES CORPORATION (US) 2006-09-05 US disclosed
EP-1567675-A4 METHODS FOR USING PRIMERS THAT ENCODE ONE STRAND OF A DOUBLE-STRANDED PROMOTER EPICT TECHNOLOGIES (US) 2006-05-10 EP disclosed
US-6277603-B1 PEPTIDE NUCLEIC ACID (PNA); THE DNA PORTION IS COMPOSED OF SUBUNITS OF AT LEAST ONE 2'-DEOXYNUCLEOTIDES; INCREASED NUCLEASE RESISTANCE; ACTIVATE RNASE H ENZYME, USE FOR IN VITRO MODIFICATION OF RNA ISIS PHARMACEUTICALS, INC. 2001-08-21 US disclosed
EP-0590082-B1 ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE RAS GENE ISIS PHARMACEUTICALS INC (US) 1999-10-27 EP disclosed
EP-0734391-A4 PNA-DNA-PNA CHIMERIC MACROMOLECULES ISIS PHARMACEUTICALS INC (US) 1998-02-25 EP disclosed
US-5700922-A INCREASED NUCLEASE RESISTANCE, INCREASED BINDING AFFINITY TO COMPLEMENTARY STRANDS; MEDICAL DIAGNOSIS, THERAPY ISIS PHARMACEUTICALS, INC. (US) 1997-12-23 US disclosed
US-5582986-A OLIGONUCLEOTIDE TARGETED TO CODON 12 OF HUMAN H-RAS GENE, COMPLEMENTARY AND HYBRIDIZES TO MESSENGER RNA TO INTERFERE WITH NORMAL ROLE IN CELL, CAUSING LOSS OF FUNCTION ISIS PHARMACEUTICALS, INC. (US) 1996-12-10 US disclosed
EP-0734391-A1 PNA-DNA-PNA CHIMERIC MACROMOLECULES ISIS PHARMACEUTICALS, INC. (US) 1996-10-02 EP disclosed
WO-1995014706-A1 PNA-DNA-PNA CHIMERIC MACROMOLECULES ISIS PHARMACEUTICALS, INC. (US) 1995-06-01 WO disclosed
EP-0590082-A4 ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE RAS GENE. ISIS PHARMACEUTICALS INC (US) 1995-04-12 EP disclosed
EP-0590082-A1 ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE RAS GENE ISIS PHARMACEUTICALS, INC. (US) 1994-04-06 EP disclosed
WO-1992022651-A1 ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE RAS GENE ISIS PHARMACEUTICALS, INC. (US) 1992-12-23 WO disclosed